Format

Send to

Choose Destination
Cancer Cell. 2014 Feb 10;25(2):135-6. doi: 10.1016/j.ccr.2014.01.026.

Molecular subtyping of invasive bladder cancer: time to divide and rule?

Author information

1
Section of Experimental Oncology, Leeds Institute of Cancer and Pathology, University of Leeds, St. James's University Hospital, Beckett Street, Leeds, West Yorkshire LS9 7TF, UK.
2
Section of Experimental Oncology, Leeds Institute of Cancer and Pathology, University of Leeds, St. James's University Hospital, Beckett Street, Leeds, West Yorkshire LS9 7TF, UK. Electronic address: m.a.knowles@leeds.ac.uk.

Abstract

Therapeutic decisions for muscle-invasive bladder cancer (MIBC) are largely based on histopathologic characteristics. In this issue of Cancer Cell, Choi and colleagues report three molecular subtypes of MIBC with the potential to guide prognosis, patient stratification, and treatment.

PMID:
24525229
DOI:
10.1016/j.ccr.2014.01.026
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center